South Korea: Fair use, non-use, and proper use of trademarks Min Son of Hanol IP & Law considers the use of a re-filing strategy against non-use cancellation By Min Son August 27 2021
South Korea allows data exclusivity for pediatric drugs approved through foreign clinic... Min Son of Hanol IP & Law summarises the eligible drugs, the re-examination period and strategies available for companies By Min Son July 14 2021
South Korea: Supreme Court’s en banc ruling drops registration defence for later-regist... Min Son of Hanol IP & Law explains how the recent Supreme Court en banc ruling changes precedents on infringement by the use of later-registered trademarks By Min Son May 20 2021
Drug pricing policy in South Korea revised to ‘tiered pricing system’ Min Son of Hanol IP & Law describes how patent challenges have become even more important under the revised drug pricing framework in South Korea By Min Son April 14 2021
South Korea: Filing and managing pharmaceutical trademarks Min Son of Hanol IP & Law looks at how the Korean Intellectual Property Office (KIPO) and the Korean courts have judged the registrability and validity of pharmaceutical trademarks according... By Min Son February 19 2021
Drug patent expiry in 2021: Opportunities and challenges in the Korean market Min Son of Hanol IP & Law looks ahead at the key deadlines in the South Korean drug patent market for 2021 By Min Son January 12 2021
